Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

Oliver Warren, Kaushik Mandal, Vassilis Hadjianastassiou, Lisa Knowlton, Sukhmeet Panesar, Kokotsakis John, Ara Darzi, Thanos Athanasiou

Research output: Contribution to journalReview article

103 Citations (Scopus)

Abstract

Postoperative hemorrhage is a common complication in cardiac surgery, and it is associated with a considerable increase in morbidity, mortality, and cost. Recombinant activated factor VII (rFVIIa) is an emerging hemostatic agent, increasingly used in cardiac surgery. This article systematically reviews the evidence regarding the efficacy, safety, and cost of rFVIIa in this setting. Although definitive evidence from randomized controlled trials is lacking, the use of rFVIIa in patients experiencing refractory postoperative hemorrhage seems promising and relatively safe. However further research is required to definitively establish its clinical utility in the postoperative cardiac patient.

Original languageEnglish
Pages (from-to)707-714
Number of pages8
JournalAnnals of Thoracic Surgery
Volume83
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint Dive into the research topics of 'Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review'. Together they form a unique fingerprint.

  • Cite this

    Warren, O., Mandal, K., Hadjianastassiou, V., Knowlton, L., Panesar, S., John, K., Darzi, A., & Athanasiou, T. (2007). Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review. Annals of Thoracic Surgery, 83(2), 707-714. https://doi.org/10.1016/j.athoracsur.2006.10.033